Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study

Niklas Worm Andersson, Emilia Myrup Thiesson, Jørgen Vinsløv Hansen, Anders Hviid
doi: https://doi.org/10.1101/2023.01.21.23284855

Article Information

doi 
https://doi.org/10.1101/2023.01.21.23284855
History 
  • January 22, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Niklas Worm Andersson, MD1,*,
  2. Emilia Myrup Thiesson, MSc1,
  3. Jørgen Vinsløv Hansen, MSc1 and
  4. Anders Hviid, DrMedSci1,2
  1. 1Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
  2. 2Pharmacovigilance Research Center, Department of Drug Development and Clinical Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  1. ↵*Corresponding author:
    Niklas Worm Andersson, Department of Epidemiology Research, Statens Serum Institut, Copenhagen S 2300, Denmark, email: nian{at}ssi.dk, telephone: +45 3268 3159
Back to top
Posted January 22, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Safety of bivalent omicron-containing mRNA-booster vaccines: a nationwide cohort study
Niklas Worm Andersson, Emilia Myrup Thiesson, Jørgen Vinsløv Hansen, Anders Hviid
medRxiv 2023.01.21.23284855; doi: https://doi.org/10.1101/2023.01.21.23284855
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area